Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia and New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was founded in 1897 and is headquartered in Basel, Switzerland.

msh id	COM:LONZA
symbol	LONN
name	Lonza Group AG
homepage url	https://www.lonza.com
country	CH
sector	-
industry	-
market	STOCKS
employee count	17.9K
crunchbase url	-
linkedin url	-
founders	-

market cap	31.42B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.1
growth cost of revenue	0.13
growth depreciation and amortization	0.04
growth ebitda	0.02
growth ebitda ratio	-0.06
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-1
growth gross profit	-0.01
growth gross profit ratio	-0.09

COM:LONZA

Lonza Group AG

Last Close

517.00

21/11 16:31

Market Cap

31.42B

Beta: -

Volume Today

131.18K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	5.92B
cost of revenue	5.92B
depreciation and amortization	685.71M
ebitda	2.19B
ebitda ratio	0.29
eps	9.81
eps diluted	9.81
operating expenses	1.01B
operating income	1.5B
operating income ratio	0.2

accounts receivables	-
capital expenditure	-1.89B
cash at beginning of period	1.48B
cash at end of period	1.62B
inventory	1.75B
working capital ttm	2.64B

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-